Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Weill Medical College of Cornell University
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Astellas Pharma Inc
M.D. Anderson Cancer Center
GI Innovation, Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Neonc Technologies, Inc.
University of California, San Francisco
Merck Sharp & Dohme LLC
Essen Biotech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Genenta Science
University of California, Davis
University of California, Davis
Takeda
Merck Sharp & Dohme LLC
Inhibrx Biosciences, Inc
University of Iowa
Twinpig Biolab, Inc.
BicycleTx Limited
Dana-Farber Cancer Institute
Dragonfly Therapeutics
BioXcel Therapeutics Inc
Maastricht University Medical Center
Scancell Ltd
Vyriad, Inc.
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
NuCana plc
Medicenna Therapeutics, Inc.
OncoC4, Inc.
Mural Oncology, Inc
Aprea Therapeutics
Hoosier Cancer Research Network
University of Colorado, Denver
RAPT Therapeutics, Inc.
Nimbus Therapeutics
GI Innovation, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Sumitomo Pharma America, Inc.
Advaxis, Inc.
GeneMedicine Co., Ltd.